Back to Search
Start Over
Argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
- Source :
- Plus Company Updates. September 19, 2018
- Publication Year :
- 2018
-
Abstract
- Amsterdam: ARGENX SE has issued the following news release: Breda, the Netherlands / Ghent, Belgium - Argenx (Euronext & Nasdaq: ARGX) today announced positive topline results from its Phase 2 [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.554894708